z-logo
open-access-imgOpen Access
The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing Quillaja saponin components QH‐A, QH‐C and ISCOPREP TM 703
Author(s) -
Hu KeFei,
Regner Matthias,
Siegrist ClaireAnne,
Lambert Paul,
Chen Margaret,
Bengtsson Karin Lövgren,
Morein Bror
Publication year - 2005
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1016/j.femsim.2004.08.010
Subject(s) - saponin , biology , virology , paramyxoviridae , respiratory system , virus , pneumovirus , microbiology and biotechnology , viral disease , medicine , alternative medicine , pathology , anatomy
A successful vaccine against human RSV (HRSV) is likely to induce a Th1 or a balanced Th1/TH2 cytokine response. We tested a panel of HRSV immunostimulating complexes (ISCOMs) containing different Quillaja saponin fractions (QH‐A, QH‐C, and 703: a mixture of 70% QH‐A and 30% QH‐C) with different immunological properties for their capacity of inducing innate and acquired immune responses. The HRSV 703 ISCOMs induced the strongest innate and acquired immune responses, followed by RSV QH‐C and QH‐A ISCOMs. All three formulations induced various degrees of Th1 bias response with prominent production of IFN‐γ being 10–50 times higher than that of IL‐4 and IL‐5. The HRSV specific IgG isotype profile correlated with the predominant secretion of Th1 cytokines, with strong induction of IgG2a antibodies. The 703 ISCOMs induced the most pronounced Th1 profile followed by QH‐C and QH‐A ISCOMs. The high incorporation of F protein in these ISCOMs compared to G protein combined with the Th1 biased nature of ISCOM are likely to be the causes to promote a Th1 type of profile. The prospect to formulate an RSV ISCOM formulation with an optimal Th1/Th2 balance is in reach particularly in view of the versatile properties of the ISCOM concept.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here